studies

1302A AASLD ABSTRACTS HEPATOLOGY, October, 2015
CVC and PGZ exposures were slightly lower when both drugs
were co-administered, with a modest decrease in steady-state
C max
and AUC 0–tau
for both drugs, whereas C min
remained
unchanged; GMRs for both drugs were ≥0.80 (Table). Effects
of co-administration on PGZ M-III and M-IV metabolites were
less pronounced, with 90% CI for systemic exposure ratios
within the 0.80–1.25 ‘no effect’ range for all 3 PK parameters
(data not shown). Combination treatment was well tolerated,
with no serious AEs or AEs leading to discontinuation. All AEs
were of mild severity and the 2 most commonly reported were
headache and fatigue. Conclusions: Co-administration of CVC
and PGZ was well tolerated and resulted in a modest interaction
that was not considered clinically significant, which suggests
that dose adjustment is not required when both drugs are
used in combination.
(62.1%) male, with a mean age of 57.7 years. 54 (47%) had
not ultrasonography signals of NAFLD. Between those with
NAFLD (n=61; 53.1%), 34 (29,6%) had NAFLD grade I, 19
(16,5%) grade II and 8 (7%) grade III. 26 (22.4%) patients
had no signals of CAD on their coronary angiography. In 50
(43.1%), serious injury has found. NAFLD showed correlation
with CAD in 57 (64.04%) patients (p 25kg/m 2 ), and 15 patients with
alcoholic (ASH) cirrhosis. Hemostatic status was assessed by
basal and agonist-induced platelet activation using flow cytometry,
thrombin generation testing, thromboelastography (TEG),
a plasma-based clot lysis assay, and an analysis of fibrin pore
structure by permeation analyses. Results: Basal and agonist-induced
platelet activation were comparable between patients
with NAFLD and controls, but agonist-induced platelet activation
was decreased in patients with cirrhosis. Thrombomodulin-modified
thrombin generation was comparable between
patients and controls, although patients with cirrhosis had a
reduced anticoagulant response to thrombomodulin. TEG test
results were comparable between controls and non-cirrhotic
NAFLD patients, but revealed moderate hypocoagulability
in cirrhosis. Plasma fibrinolytic potential was decreased in
NAFLD, but accelerated fibrinolysis was observed in ASH cirrhosis.
Clot permeability was decreased in overweight controls
and patients with NAFLD. Platelet activity, thrombin generation,
and clot lysis test results showed a higher variability in
patients than in controls, suggesting individual patients may
have a more thrombogenic hemostatic profile. Conclusions: The